StockpollyBeta
ChatSearch/
Get AppSign in
Menu
Sign in
CategoryChatSearchMaster portfoliosResearch firmsBlog
Markets
Global MarketsHeatmapAI MapScreener
Tools
P/E CompareComparePortfolio
Company
AboutPricing
ContactFeedback
AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions
momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks
PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12
Popularity #2,966Earnings are out
BLSM · NASDAQ · Biotechnology

BlossomHill Therapeutics (BLSM)

BLSM

Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.

$22.80
vs last close−2.45 (−9.70%)
OverviewEarningsFinancialsOwnershipNews

News type

  1. BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

    GlobeNewsWireSep 18

  2. BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

    GlobeNewsWireSep 15

  3. BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)

    Defense WorldSep 9Other

  4. BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

    GlobeNewsWireSep 1Clinical

  5. BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock

    Defense WorldAug 11

  6. BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

    GlobeNewsWireAug 6

  7. BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise

    Seeking AlphaAug 5

β 1.24briefsthe tapeclosesdividendstranscriptswiresliquidityclosesminutesYoY +18%threadsTSLAthreadsthreadsmarginsafter-hrstranscriptsmomentumVIX 14.2minutesrumorsupgradesQ3estimatesnewsflowbuybacksPCEthreadsvolatility13Fnarrativesflowsmomentumdowngradesyield curvesDXYdowngradessessions52w hiheadlinesyield curvesdowngradessentimentvolatilityyield curvesrumorsβ 1.24volumesfuturesforecaststickerspre-mktforecastschatterliquidityEPS 4.12newsflownoisedrawdownsGOOGLupgradesconsensuswires8-KliquidityconsensuswhispersMSFTheadlinespositioningbriefsthreadsEPS 4.12guidanceminutesnewsflow+0.8%cyclesestimates+2.41%marginsmarginsthreads2s10sliquiditycyclesnarrativesrumorsbuybacksvolumesPMI 52.1cycleschatter2s10stranscriptsconsensusmargins
GDPclosesYoY +18%buybacksnewsflow13FrevisionsflowsT+1positioningrevisionsnewsflowconsensusvolumesfilingsAAPLfuturesYoY +18%futuresmarginsflowsvolatilityrevisionsDXYwhispersearnings callspositioningAVGOcatalystsyield curvesMETA10-Kconsensus
P/E 28.4catalystsspx 0dtecatalystsbid/askvolatilityheadlinesguidancedrawdowns
Stockpolly
An agent-based financial analysis engine for public markets.
© 2026 Stockpolly. All rights reserved.
Company
AboutPricing
Legal
TermsPrivacy
Support
ContactFeedback